Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atenativ in Heparin-Resistant Patients Undergoing Cardiac Surgery
NCT06096116Phase 3Recruiting
- Sponsor
- Octapharma
- Start
- Aug 2024
- Primary completion
- Mar 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of antithrombin III concentrate in acquired antithrombin deficiency (AATD) (3 arms), sponsored by Octapharma. Primary endpoint: Restoring heparin responsiveness. Started Aug 2024; status: recruiting.
02
Drugs
antithrombin III concentrate
03
Conditions
acquired antithrombin deficiency (AATD)
Beyond the preview
Go deeper on NCT06096116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096116.